

Open randomised study of previously untreated metastatic prostate cancer patients comparing intermittent to continuous treatment with cyproterone acetate: evaluation of step-up therapy adding an luteinising hormone releasing hormone agonist upon progression is included

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 20/08/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M F Wildhagen

Contact details
Erasmus MC
P.O. Box 2040
Rotterdam
Netherlands
3000 CA
+31 (0)10 463 4191
m.wildhagen@erasmusmc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

A309904

Study information

Scientific Title

Open randomised study of previously untreated metastatic prostate cancer patients comparing intermittent to continuous treatment with cyproterone acetate: evaluation of step-up therapy adding an luteinising hormone releasing hormone agonist upon progression is included

Acronym

RSG-CPA study

Study objectives

Intermittent androgen deprivation using Cyproterone Acetate (CPA) oral monotherapy improves the overall quality of life while achieving similar control of tumour growth to that attained by continuous CPA treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Randomised, active controlled, parallel group multicentre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Prostate Cancer

Interventions

CPA 300 mg/day continuous versus CPA 300 mg/day intermittent

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Cyproterone Acetate (CPA) oral monotherapy

Primary outcome measure

1. Time to PSA progression after at least three months of continuous CPA
2. Time to clinical disease progression after at least three months of continuous CPA
3. Quality of life
4. The ratio and length of time without anti-androgenic treatment in the intermittent arm of the trial

Secondary outcome measures

1. Time to secondary PSA progression after castration
2. Time to clinical disease progression after castration
3. Time to disease specific mortality
4. Overall mortality (all causes)

Overall study start date

01/01/2000

Completion date

31/12/2003

Eligibility

Key inclusion criteria

1. Histologically or cytologically proven prostate cancer
2. M1a, M1b or M1c, irrespective of T-stage or N-stage
3. Increased Prostate Specific Antigen (PSA) serum level: PSA greater than or equal to 20 ng/ml and PSA less than 1000 ng/ml
4. World Health Organisation (WHO) performance status zero, one or two
5. No specific treatment for prostate cancer except for radical prostatectomy, Transurethral Resection of the Prostate (TURP) or radical radiotherapy. Any neo-adjuvant treatment prior to curative treatment must have been completed more than six months before entering the study
6. Signed informed consent

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

800

Key exclusion criteria

1. N+ M0, patients with regional lymph node metastases only are excluded
2. Orchiectomy
3. Testosterone in the castration range at registration
4. Life expectancy of less than 12 months
5. Presence or history of other neoplasms, unless considered cured (no evidence of tumour or at least five years)
6. Presence of progressive fatal disease other than prostate cancer
7. Presence of liver diseases (Aspartate Aminotransferase [AST] or Alanine Aminotransferase [ALT] higher than 25 times upper limit of normal)
8. Presence of sickle cell anaemia
9. Clinically relevant major systemic disease making implementation of the protocol or interpretation of the study results difficult
10. History of or presently known depressions or psychiatric disorders
11. Probable non-compliance to trial protocol
12. Hypersensitivity to CPA

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2003

Locations**Countries of recruitment**

Netherlands

Study participating centre

Erasmus MC

Rotterdam

Netherlands

3000 CA

Sponsor information**Organisation**

Erasmus Medical Centre (Netherlands)

Sponsor details

Dr Molewaterplein 40/50
Rotterdam
Netherlands
3000 CA

Sponsor type

University/education

Website

<http://www.erasmusmc.nl/>

ROR

<https://ror.org/018906e22>

Funder(s)

Funder type

Industry

Funder Name

Schering AG (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		21/11/2013	20/08/2021	Yes	No